| Returns | 1W : 1.1% , 1M : -5.2%,1Y : 66.9% |
| Peers & Returns | 1W | 1M | 1Y |
| FDC LTD | 1.1% | -5.2% | 66.9% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -1% | 5.9% | 11.3% |
| DR REDDYS LABORATORIES LTD | 0.9% | -3.7% | 62.7% |
| DIVIS LABORATORIES LTD | 3.4% | 15.6% | 100.1% |
| CIPLA LTD | 0.5% | -1.4% | 54.6% |
| BIOCON LTD | -2% | 0.7% | 64.3% |
| AUROBINDO PHARMA LTD | -0.9% | 8.3% | 94.4% |
| LUPIN LTD | -0.5% | -10.8% | 13.7% |
| TORRENT PHARMACEUTICALS LTD | -1.6% | -4.6% | 52.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
22.8
P/E Calculated based on EPS of 14.43
[ Mar2020 - Standalone Results ] 3.65
P/B Calculated based on Book Value of 90.18
[ Mar2020 - Standalone Results ] 4.33
P/S Calculated based on Revenues of 1300.22 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
110% 59% 60% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0 0 0 - |
0 0 0 - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
22.69% -1.57% -1.92% 0.55% |
8.8% 29.31% 32.69% 45.38% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
